FGF19 and hepatocellular carcinoma: The presence of the co‐receptor Klotho protein is essential for their activity in cells.[17] β‐Klotho is expressed in adipose tissue, the liver, and the pancreas, with the liver being a major target organ for FGF19.[18] Previous studies have demonstrated that FGF19 activates the PI3K/AKT signaling pathway in hepatocellular carcinoma (HCC).